Johnson & Johnson Contracts & Agreements

107 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Underwriting Agreement, dated February 19, 2025, among Johnson & Johnson and Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC and the...
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2025
Company Order establishing the terms of the Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 2.700% Notes due 2029
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 3.050% Notes due 2033
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 3.350% Notes due 2037
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 3.600% Notes due 2045
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 3.700% Notes due 2055
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Underwriting Agreement, dated February 18, 2025, among Johnson & Johnson and Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC, as...
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2025
Underwriting Agreement Standard Provisions (Debt) dated February 18, 2025
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2025
Company Order establishing the terms of the Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 4.500% Notes due 2027
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 4.550% Notes due 2028
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 4.700% Notes due 2030
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 4.850% Notes due 2032
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Form of 5.000% Notes due 2035
Note Agreements
Johnson & Johnson
Pharmaceuticals
2025
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 — Filed with this document
Johnson & Johnson
Pharmaceuticals
2025
Johnson & Johnson Executive Officer Cash Severance Policy — Filed with this document
Severance Agreements
Johnson & Johnson
Pharmaceuticals
2025
Underwriting Agreement, dated May 13, 2024, among Johnson & Johnson and J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets Inc., as representatives of...
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2024
Underwriting Agreement Standard Provisions (Debt), dated May 13, 2024
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2024
Underwriting Agreement, dated May 14, 2024, among Johnson & Johnson and J.P. Morgan Securities plc, Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and the...
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
NY
2024
Company Order establishing the terms of the U.S. Dollar Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2024
Form of 4.800% Notes due 2029
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Form of 4.900% Notes due 2031
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Form of 4.950% Notes due 2034
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Form of 5.250% Notes due 2054
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Company Order establishing the terms of the Euro Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2024
Form of 3.200% Notes due 2032
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Form of 3.350% Notes due 2036
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Form of 3.550% Notes due 2044
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Global Restricted Share Unit Award Agreement granted to John Reed on May 1, 2023 under the 2022 Long-Term Incentive Plan Filed with this document
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2024
Johnson & Johnson Deferred Compensation Plan
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2023
Separation Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc
Separation Agreements
Johnson & Johnson
Pharmaceuticals
DE
2023
Tax Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc
Johnson & Johnson
Pharmaceuticals
DE
2023
Employee Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc
Johnson & Johnson
Pharmaceuticals
DE
2023
Intellectual Property Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc
Johnson & Johnson
Pharmaceuticals
DE
2023
Trademark Phase-Out License Agreement, dated as of April 3, 2023, by and between Johnson & Johnson and Johnson & Johnson Consumer Inc
Trademark Agreements
Johnson & Johnson
Pharmaceuticals
DE
2023
Registration Rights Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc
Registration Rights Agreements
Johnson & Johnson
Pharmaceuticals
DE
2023
JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2023
JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2023
JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL NONQUALIFIED STOCK OPTION AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2023
The Johnson & Johnson Excess Savings Plan (amended and restated as of January 1, 2022) Filed with this document
Johnson & Johnson
Pharmaceuticals
2023
Contingent Value Rights Agreement, dated as of December 22, 2022, by and between Johnson & Johnson and American Stock Transfer & Trust Company, LLC
Stock Agreements
Johnson & Johnson
Pharmaceuticals
DE
2022
Agreement and Plan of Merger, dated as of October 31, 2022, by and among Johnson & Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc
Merger Agreements
Johnson & Johnson
Pharmaceuticals
DE
2022
Form of Underwriting AgreementStandard Provisions (Debt) dated as of August 20, 2020
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2020
Company Order establishing the terms of the Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2020
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Description of Capital Stock
Stock Agreements
Johnson & Johnson
Pharmaceuticals
NY
2020
Exhibit 10(a)
Johnson & Johnson
Pharmaceuticals
2019
JOHNSON & JOHNSON 2012 LONG-TERM INCENTIVE PLAN GLOBAL NONQUALIFIED STOCK OPTION AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
CA
2018
JOHNSON & JOHNSON 2012 LONG-TERM INCENTIVE PLAN GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
CA
2018
JOHNSON & JOHNSON 2012 LONG-TERM INCENTIVE PLAN GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
CA
2018
Second Supplemental Indenture dated as of November 9, 2017 between Johnson & Johnson and The Bank of New York Mellon Trust Company, N.A., as trustee
Indenture Agreements
Johnson & Johnson
Pharmaceuticals
NY
2017
Company Order establishing the terms of the Notes
Note Agreements
Johnson & Johnson
Pharmaceuticals
2017
Form of Underwriting AgreementStandard Provisions (Debt) dated as of November 8, 2017
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
2017
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2017
[Signatures on the Next Page]
Johnson & Johnson
Pharmaceuticals
NY
2017
UNDERWRITING AGREEMENT
Underwriting Agreements
Johnson & Johnson
Pharmaceuticals
NY
2016
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2016
PRINCIPAL AMOUNT
Johnson & Johnson
Pharmaceuticals
NJ
2016
JOHNSON & JOHNSON 0.650%NOTE DUE 2024
Johnson & Johnson
Pharmaceuticals
NJ
2016
JOHNSON & JOHNSON 1.150%NOTE DUE 2028
Johnson & Johnson
Pharmaceuticals
NJ
2016
JOHNSON & JOHNSON 1.650%NOTE DUE 2035
Johnson & Johnson
Pharmaceuticals
NJ
2016
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2016
SECOND AMENDMENT TO THE SEVERANCE PAY PLAN OF JOHNSON & JOHNSON AND U.S. AFFILIATED COMPANIES (as amended and restated effective October 1, 2014)
Severance Agreements
Johnson & Johnson
Pharmaceuticals
2016
EXHIBIT B FIRST AMENDMENT TO THE SEVERANCE PAY PLAN OF JOHNSON & JOHNSON AND U.S. AFFILIATED COMPANIES (as amended and restated effective October 1, 2014)
Severance Agreements
Johnson & Johnson
Pharmaceuticals
2015
CERTIFICATION OF AMENDMENTS TO THE EXCESS BENEFIT PLAN OF JOHNSON & JOHNSON AND AFFILIATED COMPANIES
Johnson & Johnson
Pharmaceuticals
2015
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2014
CERTIFICATION OF SEVERANCE PLAN AMENDMENT AND RESTATEMENT
Severance Agreements
Johnson & Johnson
Pharmaceuticals
2014
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2013
[FORM OF FLOATING RATE NOTE]
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2013
THE JOHNSON & JOHNSON EXECUTIVE INCOME DEFERRAL PLAN Amended and Restated Effective January 1, 2010
Johnson & Johnson
Pharmaceuticals
2012
Peter M. FasoloVice President, Global Human ResourcesOne Johnson & Johnson PlazaExecutive Committee MemberNew Brunswick, NJ 08933September 27, 2012
Johnson & Johnson
Pharmaceuticals
2012
Goldman, Sachs & Co. 200 West Street New York, New York 10282-2198
Johnson & Johnson
Pharmaceuticals
NY
2012
JPMorgan Chase Bank, National Association P.O. Box 161 60 Victoria Embankment London EC4Y 0JP England
Johnson & Johnson
Pharmaceuticals
NY
2012
Compensation Arrangement for the Chairman of the Board of Directors
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON FORM OF CERTIFICATE STOCK OPTION
Stock Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON FORM OF CERTIFICATE RESTRICTED SHARE UNIT
Stock Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON 2012 LONG-TERM INCENTIVE PLAN FORM OF CERTIFICATE PERFORMANCE SHARE UNIT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2012
JOHNSON & JOHNSON 2000 STOCK OPTION PLAN (Effective April 19, 2000, as amended February 10, 2003 and October 1, 2003)
Stock Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON AMENDED AND RESTATED DEFERRED FEE PLAN FOR DIRECTORS (Amended as of January 17, 2012)
Johnson & Johnson
Pharmaceuticals
NJ
2012
Summary of Compensation Arrangements for Named Executive Officers and Directors
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON FORM OF CERTIFICATE STOCK OPTION
Stock Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON FORM OF CERTIFICATE RESTRICTED SHARE UNIT
Stock Agreements
Johnson & Johnson
Pharmaceuticals
2012
JOHNSON & JOHNSON 2005 LONG-TERM INCENTIVE PLAN FORM OF CERTIFICATE PERFORMANCE SHARE UNIT
Bonus & Incentive Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2012
EX-101 INSTANCE DOCUMENT
Johnson & Johnson
Pharmaceuticals
2011
$500 million aggregate principal amount of Floating Rate Notes due 2013
Note Agreements
Johnson & Johnson
Pharmaceuticals
2011
$500 million aggregate principal amount of Floating Rate Notes due 2013
Note Agreements
Johnson & Johnson
Pharmaceuticals
NJ
2011
AGREEMENT AND PLAN OF MERGER among JOHNSON & JOHNSON SAMSON ACQUISITION CORP. and SYNTHES, INC. Dated as of April 26, 2011 TABLE OF CONTENTS
Merger Agreements
Johnson & Johnson
Pharmaceuticals
DE
2011
VOTING AGREEMENT
Voting Agreements
Johnson & Johnson
Pharmaceuticals
DE
2011
Summary of Compensation Arrangements for Named Executive Officers and Directors
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2011
EX-101 INSTANCE DOCUMENT
Johnson & Johnson
Pharmaceuticals
2010
JOHNSON & JOHNSON COMPANY ORDER
Johnson & Johnson
Pharmaceuticals
2010
EX-101 INSTANCE DOCUMENT
Johnson & Johnson
Pharmaceuticals
2010
EX-101 INSTANCE DOCUMENT
Johnson & Johnson
Pharmaceuticals
NJ
2009
EX-10.J: AMENDMENTS TO CERTIFICATE OF EXTRA COMPENSATION PLAN
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2009
EX-10.L: AMENDMENTS TO THE DEFERRED FEE PLAN FOR DIRECTORS
Johnson & Johnson
Pharmaceuticals
2009
EX-10.N: AMENDMENTS TO THE EXECUTIVE INCOME DEFERRAL PLAN
Johnson & Johnson
Pharmaceuticals
2009
EX-10.P: AMENDMENTS TO THE JOHNSON & JOHNSON EXCESS SAVINGS PLAN
Johnson & Johnson
Pharmaceuticals
2009
EX-10.R: AMENDMENTS TO THE EXCESS BENEFIT PLAN
Johnson & Johnson
Pharmaceuticals
2009
EX-10.V: SUMMARY OF COMPENSATION ARRANGEMENTS
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2009
EX-10.W: SEVERANCE ARRANGEMENT FOR ALEX GORSKY
Severance Agreements
Johnson & Johnson
Pharmaceuticals
2009
EX-10.R: SUMMARY OF COMPENSATION ARRANGEMENTS FOR NAMED EXECUTIVE OFFICERS AND DIRECTORS
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2008
Summary of Compensation Arrangementsfor Named Executive Officers andDirectors
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2007
Summary of Employment Arrangements for Michael J. Dormer
Employment Agreements
Johnson & Johnson
Pharmaceuticals
2006
Summary of Compensation Arrangements for Named Executive Officers and Directors
Compensation Agreements
Johnson & Johnson
Pharmaceuticals
2006
Form of Affiliate Letter
Johnson & Johnson
Pharmaceuticals
2006
============================================================================================================ AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Dated as of November...
Merger Agreements
Johnson & Johnson
Pharmaceuticals
IN
2005
SETTLEMENT AGREEMENT
Settlement Agreements
Johnson & Johnson
Pharmaceuticals
2005